Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 102

1.

3,3'-Diindolylmethane Inhibits TNF-α- and TGF-β-Induced Epithelial-Mesenchymal Transition in Breast Cancer Cells.

Lee J.

Nutr Cancer. 2019;71(6):992-1006. doi: 10.1080/01635581.2019.1577979. Epub 2019 Apr 29.

PMID:
31032639
2.

Activation of COUP-TFI by a Novel Diindolylmethane Derivative.

Yoon K, Chen CC, Orr AA, Barreto PN, Tamamis P, Safe S.

Cells. 2019 Mar 7;8(3). pii: E220. doi: 10.3390/cells8030220.

3.

Relations between approved platinum drugs and non-coding RNAs in mesothelioma.

Biersack B.

Noncoding RNA Res. 2018 Aug 30;3(4):161-173. doi: 10.1016/j.ncrna.2018.08.001. eCollection 2018 Dec. Review.

4.

3, 3'-Diindolylmethane-encapsulated chitosan nanoparticles accelerate molecular events during chemical carcinogen-induced mammary cancer in Sprague Dawley rats.

Isabella S, Mirunalini S.

Breast Cancer. 2019 Jul;26(4):499-509. doi: 10.1007/s12282-019-00950-x. Epub 2019 Jan 25.

PMID:
30684233
5.

3,3'-Diindolylmethane Encapsulated Chitosan Nanoparticles Accelerates Inflammatory Markers, ER/PR, Glycoprotein and Mast Cells Population During Chemical Carcinogen Induced Mammary Cancer in Rats.

Isabella S, Mirunalini S, Pandiyan K.

Indian J Clin Biochem. 2018 Oct;33(4):397-405. doi: 10.1007/s12291-017-0701-2. Epub 2017 Sep 23.

PMID:
30319185
6.

3,3'-Diindolylmethane enhances apoptosis in docetaxel-treated breast cancer cells by generation of reactive oxygen species.

Lanza-Jacoby S, Cheng G.

Pharm Biol. 2018 Dec;56(1):407-414. doi: 10.1080/13880209.2018.1495747.

7.

Advising Women Undergoing Treatment for Breast Cancer: A Narrative Review.

Lemanne D, Maizes V.

J Altern Complement Med. 2018 Sep/Oct;24(9-10):902-909. doi: 10.1089/acm.2018.0150. Review.

PMID:
30247957
8.

Towards Resolving the Pro- and Anti-Tumor Effects of the Aryl Hydrocarbon Receptor.

Narasimhan S, Stanford Zulick E, Novikov O, Parks AJ, Schlezinger JJ, Wang Z, Laroche F, Feng H, Mulas F, Monti S, Sherr DH.

Int J Mol Sci. 2018 May 7;19(5). pii: E1388. doi: 10.3390/ijms19051388.

9.

Natural polymer functionalized graphene oxide for co-delivery of anticancer drugs: In-vitro and in-vivo.

Deb A, Andrews NG, Raghavan V.

Int J Biol Macromol. 2018 Jul 1;113:515-525. doi: 10.1016/j.ijbiomac.2018.02.153. Epub 2018 Feb 27.

PMID:
29496437
10.

Treatment with Phytoestrogens Reversed Triclosan and Bisphenol A-Induced Anti-Apoptosis in Breast Cancer Cells.

Lee GA, Choi KC, Hwang KA.

Biomol Ther (Seoul). 2018 Sep 1;26(5):503-511. doi: 10.4062/biomolther.2017.160.

11.

Inhibitory effects of 3,3'-diindolylmethane on epithelial-mesenchymal transition induced by endocrine disrupting chemicals in cellular and xenograft mouse models of breast cancer.

Lee GA, Hwang KA, Choi KC.

Food Chem Toxicol. 2017 Nov;109(Pt 1):284-295. doi: 10.1016/j.fct.2017.08.037. Epub 2017 Aug 24.

PMID:
28844962
12.

Two likely targets for the anti-cancer effect of indole derivatives from cruciferous vegetables: PI3K/Akt/mTOR signalling pathway and the aryl hydrocarbon receptor.

Popolo A, Pinto A, Daglia M, Nabavi SF, Farooqi AA, Rastrelli L.

Semin Cancer Biol. 2017 Oct;46:132-137. doi: 10.1016/j.semcancer.2017.06.002. Epub 2017 Jun 13. Review.

PMID:
28596013
13.

A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen.

Thomson CA, Chow HHS, Wertheim BC, Roe DJ, Stopeck A, Maskarinec G, Altbach M, Chalasani P, Huang C, Strom MB, Galons JP, Thompson PA.

Breast Cancer Res Treat. 2017 Aug;165(1):97-107. doi: 10.1007/s10549-017-4292-7. Epub 2017 May 30.

14.

The Aryl Hydrocarbon Receptor (AhR) as a Drug Target for Cancer Chemotherapy.

Safe S, Cheng Y, Jin UH.

Curr Opin Toxicol. 2017 Feb;2:24-29. doi: 10.1016/j.cotox.2017.01.012. Epub 2017 Feb 1.

15.

BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo.

Cheng S, Castillo V, Welty M, Alvarado M, Eliaz I, Temm CJ, Sandusky GE, Sliva D.

BMC Complement Altern Med. 2017 Feb 16;17(1):115. doi: 10.1186/s12906-017-1621-7.

16.

AHR/CYP1A1 interplay triggers lymphatic barrier breaching in breast cancer spheroids by inducing 12(S)-HETE synthesis.

Nguyen CH, Brenner S, Huttary N, Atanasov AG, Dirsch VM, Chatuphonprasert W, Holzner S, Stadler S, Riha J, Krieger S, de Martin R, Bago-Horvath Z, Krupitza G, Jäger W.

Hum Mol Genet. 2016 Nov 15;25(22):5006-5016. doi: 10.1093/hmg/ddw329.

PMID:
28171546
17.

Novel diindolylmethane derivatives based NLC formulations to improve the oral bioavailability and anticancer effects in triple negative breast cancer.

Godugu C, Doddapaneni R, Safe SH, Singh M.

Eur J Pharm Biopharm. 2016 Nov;108:168-179. doi: 10.1016/j.ejpb.2016.08.006. Epub 2016 Aug 30.

18.

Development of novel application of 3,3'-diindolylmethane: sensitizing multidrug resistance human breast cancer cells to γ-irradiation.

Wang W, Lv M, Wang Y, Zhang J.

Pharm Biol. 2016 Dec;54(12):3164-3168. Epub 2016 Jun 16.

PMID:
27307186
20.

Chemopreventive properties of 3,3'-diindolylmethane in breast cancer: evidence from experimental and human studies.

Thomson CA, Ho E, Strom MB.

Nutr Rev. 2016 Jul;74(7):432-43. doi: 10.1093/nutrit/nuw010. Epub 2016 May 31. Review.

Supplemental Content

Loading ...
Support Center